title: Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
abstract: Although recent studies have suggested that cessation of imatinib (IM) in chronic myeloid leukemia patients can be associated with sustained response, further validation is needed to explore predictive factors. In a prospective, multicenter study, chronic phase patients were eligible for cessation of IM therapy after more than 3 years if they had no detectable BCR-ABL1 transcript for at least 2 years. A total of 48 patients with a median age of 47 years (19-74 years) were enrolled. Twenty patients received IM for post-transplant relapse. After a median follow-up of 15.8 months (1.4-28.2 months) after IM discontinuation, nine of the non-transplant group lost undetectable molecular residual disease (UMRD) and major molecular response (MMR), whereas none of the 20 patients in the transplant group experienced UMRD loss. Probabilities for sustained MMR and UMRD were 64.4% and 66.3% in the non-transplant group, respectively. Of nine patients re-treated with IM, eight patients re-achieved MMR at a median of 1.7 months (0.9-2.8 months). Seven of these patients re-achieved UMRD at a median of 5.6 months (2.8-12.1 months). Previous transplantation, IM duration, and UMRD duration were significantly associated with sustained molecular responses. Our data strongly suggest that immunological control contributes to sustained suppression of residual leukemia cell expansion and that IM can be safely discontinued in patients with post-transplant relapse.
authors: Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
authors: Sung-Eun
authors: SE
authors: Lee
authors: Soo Young
authors: SY
authors: Choi
authors: Ju-Hee
authors: JH
authors: Bang
authors: Soo-Hyun
authors: SH
authors: Kim
authors: Eun-Jung
authors: EJ
authors: Jang
authors: Ji-Young
authors: JY
authors: Byeun
authors: Jin-Eok
authors: JE
authors: Park
authors: Hye-Rim
authors: HR
authors: Jeon
authors: Yun Jeong
authors: YJ
authors: Oh
authors: Hyeoung-Joon
authors: HJ
authors: Kim
authors: Yeo-Kyeoung
authors: YK
authors: Kim
authors: Joon Seong
authors: JS
authors: Park
authors: Seong Hyun
authors: SH
authors: Jeong
authors: Sung-Hyun
authors: SH
authors: Kim
authors: Dae Young
authors: DY
authors: Zang
authors: Sukjoong
authors: S
authors: Oh
authors: Dong Hoe
authors: DH
authors: Koo
authors: Hawk
authors: H
authors: Kim
authors: Young Rok
authors: YR
authors: Do
authors: Jae-Yong
authors: JY
authors: Kwak
authors: Jeong-A
authors: JA
authors: Kim
authors: Dae-Young
authors: DY
authors: Kim
authors: Yeung-Chul
authors: YC
authors: Mun
authors: Michael J
authors: MJ
authors: Mauro
authors: Dong-Wook
authors: DW
authors: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate